Great Lakes Retirement Inc. Has $988,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

Great Lakes Retirement Inc. raised its position in Novo Nordisk A/S (NYSE:NVO) by 4.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,296 shares of the company’s stock after buying an additional 384 shares during the period. Great Lakes Retirement Inc.’s holdings in Novo Nordisk A/S were worth $988,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in shares of Novo Nordisk A/S by 4.2% in the third quarter. Brighton Jones LLC now owns 15,176 shares of the company’s stock valued at $1,807,000 after acquiring an additional 606 shares during the last quarter. YHB Investment Advisors Inc. increased its holdings in Novo Nordisk A/S by 11.3% during the 3rd quarter. YHB Investment Advisors Inc. now owns 3,284 shares of the company’s stock valued at $391,000 after purchasing an additional 334 shares in the last quarter. International Assets Investment Management LLC raised its position in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. MFA Wealth Advisors LLC boosted its stake in Novo Nordisk A/S by 184.4% in the third quarter. MFA Wealth Advisors LLC now owns 728 shares of the company’s stock worth $87,000 after purchasing an additional 472 shares in the last quarter. Finally, Lazari Capital Management Inc. boosted its stake in Novo Nordisk A/S by 13.9% in the third quarter. Lazari Capital Management Inc. now owns 1,928 shares of the company’s stock worth $230,000 after purchasing an additional 236 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 1.6 %

NVO opened at $113.94 on Friday. The firm has a 50 day simple moving average of $127.52 and a 200 day simple moving average of $131.50. Novo Nordisk A/S has a fifty-two week low of $92.94 and a fifty-two week high of $148.15. The company has a market cap of $511.31 billion, a price-to-earnings ratio of 39.02, a price-to-earnings-growth ratio of 1.52 and a beta of 0.42. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The business had revenue of $9.82 billion for the quarter, compared to the consensus estimate of $9.91 billion. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.01 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were issued a dividend of $0.5126 per share. This represents a yield of 0.7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 24.66%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, October 10th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 9th. Finally, BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.